Format

Send to

Choose Destination
BMC Pulm Med. 2018 Dec 6;18(1):188. doi: 10.1186/s12890-018-0752-z.

Elevated Hsp90-beta contributes to differential diagnosis of pleural effusion caused by lung cancer and correlates with malignant biological behavior of lung cancer.

Author information

1
Department of Respiratory Medicine, First Affiliated Hospital, Xi'an Medical University, 48 Fenghao West Road, Xi'an, 710077, China. research568rbx@yeah.net.
2
Department of Respiratory Medicine, Shenmu Hospital, Shenmu, China.
3
Department of respiratory Medicine, Jining NO.1 People's Hospital, Jining, China.
4
Institute of Epidemiology and Health Statistics, School of Public Health, Lanzhou University, Lanzhou, China.
5
Department of Respiratory Medicine, Gansu Provincial Hospital, Lanzhou, China.

Abstract

BACKGROUND:

Hsp90-beta has been investigated to be correlated with the occurrence and development of tumor. The intention of this research was to test the level of Hsp90-beta in malignant pleural effusion (MPE) of patients with lung cancer and disclose the clinical significance of Hsp90-beta as a potential tumor marker for differential diagnosis of pleural effusion caused by lung cancer.

METHODS:

The level of Hsp90-beta was determined using enzyme-linked immunosorbent assay. Calculations of the Hsp90-beta threshold, the sensitivity and specificity for distinguishing MPE from benign pleural effusion were performed using receiver operator characteristic curve.

RESULTS:

The level of Hsp90-beta in MPE of lung cancer patients was higher than that in control individuals (P < 0.05) and increased MPE Hsp90-beta was correlated with the pathological differentiation, tumor size and lymphatic metastasis (P < 0.05). The cutoff value of Hsp90-beta produced by receiver operator characteristic curve for distinguishing lung cancer from control individuals were 1.659 ng/mL and the sensitivity and specificity were 93.46 and 79%.

CONCLUSIONS:

Increased Hsp90-beta in MPE was correlated with malignant biological behavior of lung cancer patients, indicating that the level of Hsp90-beta could be a tool of referential value for differential diagnosis of pleural effusion caused by lung cancer.

KEYWORDS:

Biomarker; Diagnosis; Hsp90-beta; Lung cancer; MPE; Malignant pleural effusion

PMID:
30522463
PMCID:
PMC6282391
DOI:
10.1186/s12890-018-0752-z
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center